We caught up with Dr. Andrew Blauvelt (Oregon Medical Research Center, Portland, OR, USA) to discuss the rationale for and findings from the proof-of-concept study of eblasakimab in moderate-to-severe atopic dermatitis.
The abstract ‘Eblasakimab, a human anti-IL-13 receptor monoclonal antibody, in adult patients with moderate-to-severe atopic dermatitis: a randomized, double-blinded, placebo-controlled, proof-of-concept study’ was presented at AAD-VMX 2022, 25-29 March.
- What has been the impact of anti-IL receptor antibodies in the treatment of atopic dermatitis? (0:14)
- What unmet needs remain in the treatment of moderate-to-severe atopic dermatitis? (0:59)
- What is eblasakimab and what is the rationale for its use in atopic dermatitis? (2:19)
- Could you tell us a little about the proof-of-concept study and its findings? (3:40)
- What will be the next steps in the clinical development of eblasakimab? (5:38)
Disclosures: Andrew Blauvelt has served as a speaker/received honoraria from AbbVie and UCB, served as a scientific adviser/received honoraria from AbbVie, Abcentra, Aligos, Almirall, Amgen, Anaptysbio, Arcutis, Arena, Aslan, Athenex, Boehringer Ingelheim, Bristol-Myers Squibb, Dermavant, EcoR1, Eli Lilly and Company, Evommune, Forte, Galderma, HighlightII Pharma, Incyte, Janssen, Landos, Leo, Merck, Novartis, Pfizer, Rapt, Regeneron, Sanofi Genzyme, Sun Pharma, UCB Pharma, Vibliome, and Xencor, and has acted as a clinical study investigator/institution has received clinical study funds from AbbVie, Amgen, Arcutis, Athenex, Boehringer Ingelheim, Bristol-Myers Squibb, Dermavant, Eli Lilly and Company, Galderma, Incyte, Janssen, Leo, Merck, Novartis, Pfizer, Regeneron, Sun Pharma, and UCB Pharma.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the AAD-VMX annual meeting 2022.
Share this Video
Related Videos In Atopic Dermatitis
Gil Yosipovitch, EADV 2022: Lebrikizumab Monotherapy for Moderate to Severe Atopic Dermatitis
ADvocate 1 (NCT04146363) and ADvocate 2 (NCT04178967) are phase 3, randomised, double-blind, placebo-controlled trials, investigating lebrikizumab monotherapy in moderate to severe atopic dermatitis. touchIMMUNOLOGY caught up with Prof. Gil Yosipovitch (Miller School of Medicine, University of Miami, Miami, FL, USA) around the ADvocate 1 and ADvocate 2 phase 3 studies and the findings from his […]
Laura Carucci, EAACI 2022: Probiotic L.rhamnosus GG in Paediatric Atopic Dermatitis – Findings from the ProPAD Study
Paediatric atopic dermatitis is a common chronic skin condition in children that results in dry, itchy skin. It was a pleasure to talk with Dr. Laura Carucci (University of Naples Federico II. Naples, Italy) to discuss the aims, outcome measures and findings from the ProPAD study, investigating L.rhamnosus GG in paediatric atopic dermatitis. The abstract […]
Laura Carucci, EAACI 2022: Health Burden of Paediatric Atopic Dermatitis and Impact of Probiotic Treatment
Paediatric atopic dermatitis is a common chronic skin condition in children that results in dry, itchy skin. It was a pleasure to talk with Dr. Laura Carucci (University of Naples Federico II. Naples, Italy) to discuss the health burden of paediatric atopic dermatitis, the unmet needs in treatment and the potential of probiotic treatment. The […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!